Norovirus Challenge Study

Exclusion criteria

• . Administration/use of any investigational drug or device 30 days prior to vaccination through the active period (Day 57)
• . Administration of any licensed vaccine within 30 days prior to vaccination or planned use of the above stated during the active period (through Day 57)
• . Presence of a significant medical condition, which, in the opinion of the investigator, precludes participation in the study. Significant medical condition = for example, psychiatric conditions, or gastrointestinal disease, such as peptic ulcer, symptoms or evidence of active gastritis or gastroesophageal reflux disease, inflammatory bowel disease, alcohol or illicit drug abuse/dependency, or other laboratory abnormalities
• . Laboratory values outside the range of normal for platelet counts and the following coagulation tests: prothromibin time test (PT/INR), activated partial thromboplastine time test (aPTT) and fibrinogen
• . Any of the following history or conditions that may lead to higher risk of clotting events and/or thrombocytopenia:
• . Family or personal history of bleeding or thrombosis
• . History of heparin-related thrombotic events, and/or receiving heparin treatments
• . History of autoimmune or inflammatory disease